FOTIVDA Drug Patent Profile
✉ Email this page to a colleague
When do Fotivda patents expire, and what generic alternatives are available?
Fotivda is a drug marketed by Aveo Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has forty-six patent family members in twenty-four countries.
The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this compound. Additional details are available on the tivozanib hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Fotivda
Fotivda will be eligible for patent challenges on March 10, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 10, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for FOTIVDA
International Patents: | 46 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 99 |
Clinical Trials: | 2 |
Patent Applications: | 1,110 |
Drug Prices: | Drug price information for FOTIVDA |
What excipients (inactive ingredients) are in FOTIVDA? | FOTIVDA excipients list |
DailyMed Link: | FOTIVDA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for FOTIVDA
Generic Entry Date for FOTIVDA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FOTIVDA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aveo Oncology Pharmaceuticals | Phase 1/Phase 2 |
University of Florida | Phase 1/Phase 2 |
Genentech, Inc. | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for FOTIVDA
US Patents and Regulatory Information for FOTIVDA
FOTIVDA is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of FOTIVDA is See Plans and Pricing.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting FOTIVDA
Quinoline derivatives and quinazoline derivatives having azolyl group
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting FOTIVDA
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
International Patents for FOTIVDA
See the table below for patents covering FOTIVDA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 60226912 | See Plans and Pricing | |
Russian Federation | 2283841 | АЗОЛИЛЬНЫЕ ПРОИЗВОДНЫЕ ХИНОЛИНА И ХИНАЗОЛИНА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИХ ПРИМЕНЕНИЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (AZOLYL QUINOLINE AND QUINAZOLINE DERIVATIVES, PHARMASEUTICAL COMPOSITION CONTAINING THE SAME, USES THEREOF AND METHOD FOR TREATMENT OF DISEASES) | See Plans and Pricing |
South Korea | 100879669 | See Plans and Pricing | |
Japan | 2003012668 | QUINOLIN DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLIN DERIVATIVE | See Plans and Pricing |
Australia | 2002255284 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FOTIVDA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1382604 | CR 2018 00007 | Denmark | See Plans and Pricing | PRODUCT NAME: TIVOZANIB ELLER ET SALT ELLER SOLVAT DERAF, SAERLIGT HYDROCHLORIDMONOHYDRATET; REG. NO/DATE: EU/1/17/1215 20170829 |
1382604 | 122018000018 | Germany | See Plans and Pricing | PRODUCT NAME: TIVOZANIB ODER EIN SALZ ODER SOLVAT HIERVON; REGISTRATION NO/DATE: EU/1/17/1215 20170824 |
1382604 | CA 2018 00007 | Denmark | See Plans and Pricing | PRODUCT NAME: TIVOZANIB ELLER ET SLAT ELLER SOLVAT DERAF, SAERLIGT HYDROCHLORIDMONOHYDRATET; REG. NO/DATE: EU/1/17/1215 20170829 |
1382604 | 18C1006 | France | See Plans and Pricing | PRODUCT NAME: TIVOZANIB OU UN DE SES SELS OU DE SES SOLVATES,EN PARTICULIER LE CHLORHYDRATE MONOHYDATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829 |
1382604 | 600 | Finland | See Plans and Pricing | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |